Barclays lowered the firm’s price target on Exscientia to $9 from $10 and keeps an Overweight rating on the shares. The analyst updated the firm’s model following Exscientia’ acquisition of full rights to the CDK7 program from GT Apeiron.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAI:
- Exscientia Secures Full Rights to Novel Cancer Drug
- Exscientia pays GT Apeiron $10M upfont cash+ equity for ‘full control’ of 617
- Exscientia launches AWS AI-powered platform to advance drug discovery
- Exscientia initiated with a Buy at TD Cowen
- Class Action Lawsuit against Exscientia PLC (NASDAQ:EXAI)